On Monday, Cullinan Therapeutics Inc (NASDAQ: CGEM) was 17.47% up from the session before settling in for the closing price of $10.59. A 52-week range for CGEM has been $5.68 – $13.60.
Healthcare Sector giant saw their annual sales slid by -45.66% over the last five years. When this article was written, the company’s average yearly earnings per share was at -30.30%. With a float of $39.45 million, this company’s outstanding shares have now reached $59.08 million.
Cullinan Therapeutics Inc (CGEM) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cullinan Therapeutics Inc stocks. The insider ownership of Cullinan Therapeutics Inc is 33.22%, while institutional ownership is 77.35%. The most recent insider transaction that took place on Nov 24 ’25, was worth 49,200. In this transaction Chief Scientific Officer of this company sold 4,000 shares at a rate of $12.30, taking the stock ownership to the 138,004 shares. Before that another transaction happened on Nov 24 ’25, when Company’s Officer proposed sale 4,000 for $9.47, making the entire transaction worth $37,880.
Cullinan Therapeutics Inc (CGEM) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.73 earnings per share (EPS) during the time that was better than consensus figure (set at -0.74) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.9 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -30.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.02% during the next five years compared to -45.66% drop over the previous five years of trading.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
You can see what Cullinan Therapeutics Inc (CGEM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.68, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -3.13 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Analysing the last 5-days average volume posted by the [Cullinan Therapeutics Inc, CGEM], we can find that recorded value of 1.37 million was better than the volume posted last year of 0.63 million. As of the previous 9 days, the stock’s Stochastic %D was 50.59%.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 88.37%, which indicates a significant increase from 82.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.17 in the past 14 days, which was higher than the 0.58 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.37, while its 200-day Moving Average is $7.97. Now, the first resistance to watch is $13.25. This is followed by the second major resistance level at $14.05. The third major resistance level sits at $15.40. If the price goes on to break the first support level at $11.10, it is likely to go to the next support level at $9.75. Now, if the price goes above the second support level, the third support stands at $8.95.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
There are 59,076K outstanding shares of the company, which has a market capitalization of 734.91 million. As of now, sales total 0 K while income totals -167,380 K. Its latest quarter income was 0 K while its last quarter net income were -50,610 K.
